KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to $61.6 million.

  • Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) fell 8.75% to $61.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.6 million, marking a year-over-year decrease of 8.75%. This contributed to the annual value of $66.0 million for FY2024, which is 8.41% down from last year.
  • Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $61.6 million in Q3 2025, which was up 0.67% from $61.2 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $73.8 million for Q1 2023, and its period low was $58.4 million during Q1 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $68.6 million in 2024 and averaged $68.1 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) increased by 17.27% in 2023, and later decreased by 15.23% in 2024.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $59.7 million in 2021, then increased by 4.77% to $62.5 million in 2022, then grew by 15.23% to $72.1 million in 2023, then fell by 8.41% to $66.0 million in 2024, then declined by 8.75% to $61.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $61.6 million for Q3 2025, versus $61.2 million for Q2 2025 and $66.0 million for Q4 2024.